These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 36083119)

  • 1. Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
    Shen X; Chalkias S; Feng J; Chen X; Zhou H; Marshall JC; Girard B; Tomassini JE; Aunins A; Das R; Montefiori DC
    N Engl J Med; 2022 Sep; 387(13):1234-1236. PubMed ID: 36083119
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
    Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
    Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
    Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ
    Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762
    [No Abstract]   [Full Text] [Related]  

  • 4. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 5. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
    Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
    EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination.
    Liu YM; Lee YL; Liu CE; Chen YC; Tien N; Su WC
    Infection; 2023 Apr; 51(2):531-534. PubMed ID: 36109464
    [No Abstract]   [Full Text] [Related]  

  • 8. Audio Interview: A Look at Covid-19 Prevention and Care in 2020.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Dec; 383(27):e147. PubMed ID: 33382936
    [No Abstract]   [Full Text] [Related]  

  • 9. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
    N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.
    Yu J; Collier AY; Rowe M; Mardas F; Ventura JD; Wan H; Miller J; Powers O; Chung B; Siamatu M; Hachmann NP; Surve N; Nampanya F; Chandrashekar A; Barouch DH
    N Engl J Med; 2022 Apr; 386(16):1579-1580. PubMed ID: 35294809
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
    Rosati M; Terpos E; Agarwal M; Karalis V; Bear J; Burns R; Hu X; Papademetriou D; Ntanasis-Stathopoulos I; Trougakos IP; Dimopoulos MA; Pavlakis GN; Felber BK
    Am J Hematol; 2022 Jan; 97(1):E3-E7. PubMed ID: 34674297
    [No Abstract]   [Full Text] [Related]  

  • 12. Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.
    Hachmann NP; Miller J; Collier AY; Barouch DH
    N Engl J Med; 2022 Nov; 387(20):1904-1906. PubMed ID: 36260835
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine.
    Kumar D; Hu Q; Samson R; Ferreira VH; Hall VG; Ierullo M; Majchrzak-Kita B; Hardy W; Gingras AC; Humar A
    Am J Transplant; 2022 Aug; 22(8):2089-2093. PubMed ID: 35266606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
    Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
    Front Immunol; 2022; 13():816220. PubMed ID: 35145522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Wratil PR; Stern M; Priller A; Willmann A; Almanzar G; Vogel E; Feuerherd M; Cheng CC; Yazici S; Christa C; Jeske S; Lupoli G; Vogt T; Albanese M; Mejías-Pérez E; Bauernfried S; Graf N; Mijocevic H; Vu M; Tinnefeld K; Wettengel J; Hoffmann D; Muenchhoff M; Daechert C; Mairhofer H; Krebs S; Fingerle V; Graf A; Steininger P; Blum H; Hornung V; Liebl B; Überla K; Prelog M; Knolle P; Keppler OT; Protzer U
    Nat Med; 2022 Mar; 28(3):496-503. PubMed ID: 35090165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homing In On a SARS-CoV-2 Correlate of Protection.
    Abbasi J
    JAMA; 2022 Jan; 327(2):115. PubMed ID: 35015053
    [No Abstract]   [Full Text] [Related]  

  • 19. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.
    Qu P; Faraone J; Evans JP; Zou X; Zheng YM; Carlin C; Bednash JS; Lozanski G; Mallampalli RK; Saif LJ; Oltz EM; Mohler PJ; Gumina RJ; Liu SL
    N Engl J Med; 2022 Jun; 386(26):2526-2528. PubMed ID: 35704428
    [No Abstract]   [Full Text] [Related]  

  • 20. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
    Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
    Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.